EDAP Announces Publication of Focal One Endometriosis Study in the Journal Ultrasound in Obstetrics & Gynecology - Seite 2

About Croix-Rousse University Hospital
Based in Lyon, France, Hôpital de la Croix-Rousse is a leading complete care Institution. Among the hospital’s many specialties are: infectious and tropical diseases (with a P4 room to isolate very contagious patients), a Level 3 maternity and neonatal resuscitation service and neonatology, orthopedics, hepatic transplant for adults, gynecology and breast care, and cardiology. The hospital employs 3,107 staff members, including 792 physicians.)
  

About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market for 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm Robotic HIFU and Ablatherm Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith range of ESWL systems. For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status, regulatory approvals, market acceptance and the  continued market potential for our HIFU and lithotripsy devices. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
[phone]
[e-mail]

Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
[e-mail]